Physician profile
Brett W Sharp
NPI 1750301529
$5,219.71
in general payments reported to CMS, 2019-2025
26 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 90% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.31 · 2022: $933 · 2023: $1,386 · 2024: $1,391 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $625.00 | 2022-2024 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $622.22 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $594.23 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $510.04 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $405.16 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $382.47 | 2022-2025 | Trintellix |
| Lundbeck LLC | $363.71 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $302.26 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $291.62 | 2021-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $252.16 | 2022-2025 | Fanapt, Hetlioz |
| Indivior INC. | $157.42 | 2022-2024 | Sublocade |
| Alkermes, INC. | $134.72 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Idorsia Pharmaceuticals US INC | $83.21 | 2022-2023 | Quviviq |
| Abbvie INC. | $82.47 | 2022-2025 | |
| Biogen, INC. | $59.76 | 2024-2025 | Zurzuvae |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $52.66 | 2025 | Jornay Pm |
| Tris Pharma INC | $44.28 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $42.88 | 2022-2023 | Aplenzin |
| Corium, LLC | $39.47 | 2025 | Azstarys |
| Noven Therapeutics, LLC | $34.34 | 2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $32.77 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.32 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Tempus Ai, INC | $22.56 | 2025 | Xt Cdx |
| Acadia Pharmaceuticals INC | $21.39 | 2022 | |
| Braeburn INC. | $15.86 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $14.73 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.